EMA Issues Advice on Using NSAIDS for COVID-19

March 18, 2020
Pharmaceutical Technology Editors

Following reports, that are particularly circulating social media, questioning whether non-steroidal anti-inflammatories (NSAIDs), such as ibuprofen, worsen COVID-19, the European Medicines Agency (EMA) has issued advice.

Following reports, that are particularly circulating social media, questioning whether non-steroidal anti-inflammatories (NSAIDs), such as ibuprofen, worsen COVID-19, the European Medicines Agency (EMA) has issued advice.

In a March 18, 2020 press release, EMA specified that “there is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID-19.” The agency reported that it will be monitoring the situation closely and will review any information that comes to light in the context of the pandemic.

Current recommendations for patients and healthcare professionals for the treatment of COVID-19 are to consider all available options, including paracetamol and NSAIDs. The different types of medication offer different benefits and risks, all of which are incorporated into the product information and should be taken into consideration along with the European Union national treatment guidelines-for the most part, national treatment guidelines recommend paracetamol as a first treatment option for fever or pain.

Continuation of the use of NSAIDs, according to the approved product information, is in line with the European Union’s national treatment guidelines. The current advice for NSAIDs includes that they are used in the lowest effective dose for the shortest amount of time possible. Those patients who are already taking NSAIDs for chronic diseases should not interrupt treatment.

Source: EMA